- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02123446
A Study of Cephalexin Capsules in Healthy Participants
June 19, 2015 updated by: Eli Lilly and Company
A Randomized, Open-label, Two-period, Two-treatment, Two-sequence, Crossover Study to Evaluate the Bioequivalence of Single Doses of Two Oral Preparations in Capsules With 250 mg of Cephalexin (Keflex® Made in Mexico by Eli Lilly y Compañía de México, S.A. de C.V. vs. Keflex® Made in Italy by Facta Farmaceutici S.p.A. for Eli Lilly y Compañía de México, S.A. de C.V.) in Fasting Healthy Volunteers
The purpose of this study is to compare two different preparations of an antibiotic called cephalexin in capsules to determine if they are essentially the same.
The study has two periods.
Participants will receive one preparation of cephalexin in each period.
At least 7 hours will pass between the study periods.
The study is expected to last about 2 days for each participant, not including screening or follow-up.
Study Overview
Study Type
Interventional
Enrollment (Actual)
28
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Mexico City, Mexico, 14610
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Participation will be voluntary.
- The body mass index of participants should be between 18-27.
- Participants should have a good health status.
- Limits of variation allowed within normal values at screening will be: blood pressure (seated) up to 139 millimeters of mercury (mm Hg), for systolic, and up to 89 mm Hg for diastolic; heart rate between 60 and 100 beats per minute, and respiratory rate between 14 and 20 breaths per minute.
- Hepatitis B and C and human immunodeficiency virus (HIV) negative.
- Drug abuse or alcohol detection test approximately 12 hours before administering the study medication.
- Serum pregnancy test (beta human chorionic gonadotropin) at screening and urine pregnancy test approximately 12 hours before administering the study medication.
Exclusion Criteria:
- Participants with any clinically significant abnormality in their vital sign constants recorded at screening.
- Sponsor´s and/or site employees.
- Abnormal 12 lead electrocardiogram (ECG) that in the opinion of the investigator places the participant at an unacceptable risk for study participation, Bazett corrected QR interval (QTcB) > 470 millisecond (msec) for women and > 450 msec for men.
- Participants with history of cardiovascular, renal, hepatic, muscular, metabolic, gastrointestinal diseases, including constipation, neurological, endocrine, hematopoietic diseases, or any type of anemia, asthma, mental disease, or other organic abnormalities.
- Participants with a creatinine clearance < 80 milliliter per minute (mL/min) based on the Cockcroft-Gault equation.
- Participants requiring any medication during the study, apart from the medication which is being studied.
- Participants with history of dyspepsia, gastritis, esophagitis, duodenal or gastric ulcer.
- Participants who have been exposed to medications known as hepatic enzyme inducers or inhibitors or who have been taking potentially toxic medications within the 30 days prior.
- Participants who have received any medication, including vitamins (with or without medical prescription) or herbal-based remedies 30 days (or 7 half-lives) prior to the beginning of the study.
- Participants who have been hospitalized for any condition within six months to the beginning of the study.
- Participants who have received investigational drugs within the 60 days prior to the study.
- Participants allergic to any medication, food, or substance.
- Participants who require therapy with nephrotoxic drugs.
- Participants who have donated 450 mL of blood or more within the 60 days prior to the beginning of the study.
- Participants with history of drug and alcohol abuse.
- Participants with special diet requirement for any cause.
- Participants with positive to pregnancy test or are breastfeeding.
- Participants on hormonal treatment by any route.
- Participants who have not been recorded in the page of the Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Cephalexin (Reference)
Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods.
|
Administered orally.
Other Names:
|
ACTIVE_COMPARATOR: Cephalexin (Test)
Cephalexin manufactured in Italy by Facta administered once orally in one of two study periods.
|
Administered orally.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetics: Area Under the Concentration Versus Time Curve of Cephalexin From Time Zero to Infinity [AUC(0-∞)] of Cephalexin Following a Single Dose
Time Frame: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, and 7.0 hours in each period
|
Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, and 7.0 hours in each period
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetics: Time to Reach Maximum Observed Concentration (Tmax) of Cephalexin Following a Single Dose Maximum
Time Frame: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, and 7.0 hours in each period
|
Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, and 7.0 hours in each period
|
Pharmacokinetics: Maximum Concentration (Cmax) of Cephalexin
Time Frame: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, and 7.0 hours in each period
|
Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, and 7.0 hours in each period
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2014
Primary Completion (ACTUAL)
May 1, 2014
Study Completion (ACTUAL)
May 1, 2014
Study Registration Dates
First Submitted
April 23, 2014
First Submitted That Met QC Criteria
April 23, 2014
First Posted (ESTIMATE)
April 25, 2014
Study Record Updates
Last Update Posted (ESTIMATE)
July 15, 2015
Last Update Submitted That Met QC Criteria
June 19, 2015
Last Verified
June 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15313
- A3Q-ME-AFBP (OTHER: Eli Lilly and Company)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on Cephalexin
-
BayerCorporación Bonima S.A. de C.V.CompletedAnti-Infective AgentsMexico
-
Ottawa Hospital Research InstituteThe Ottawa Hospital Academic Medical Association; Network of Canadian Emergency...Recruiting
-
BayerCorporación Bonima S.A. de C.V.CompletedAnti-Infective AgentsMexico
-
BayerCorporación Bonima S.A. de C.V.CompletedAnti-Infective AgentsMexico
-
University of California, San FranciscoCompletedSoft Tissue InfectionsUnited States
-
Brett A FaineUniversity of California, Los AngelesNot yet recruitingPyelonephritis Acute
-
University of PennsylvaniaTerminatedThrough-and-through Lip LacerationsUnited States
-
AbbottCompletedMild to Moderate Uncomplicated Skin and Skin Structure Infections
-
Aga Khan UniversityDow University of Health Sciences; Liaquat National Hospital & Medical CollegeUnknownSurgical Site InfectionPakistan
-
University of MichiganRecruitingFacial DefectUnited States